Home

rugueux semestre serviteur 1r41hl12952401 rsk3 anchoring disruptor therapy for heart failure nih reporter Collier Connecté À plus

PLOS ONE: Evidence-based beta blocker use associated with lower heart  failure readmission and mortality, but not all-cause readmission, among  Medicare beneficiaries hospitalized for heart failure with reduced ejection  fraction
PLOS ONE: Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction

Non-invasive biosensors to detect cardiovascular changes in heart failure -  Omer Inan
Non-invasive biosensors to detect cardiovascular changes in heart failure - Omer Inan

Dynamique Spatiotemporelle de la protéine kinase AMPc dépendante dans les  myocytes cardiaques
Dynamique Spatiotemporelle de la protéine kinase AMPc dépendante dans les myocytes cardiaques

Cyclic Nucleotide Signaling and the Cardiovascular System
Cyclic Nucleotide Signaling and the Cardiovascular System

PLOS ONE: Evidence-based beta blocker use associated with lower heart  failure readmission and mortality, but not all-cause readmission, among  Medicare beneficiaries hospitalized for heart failure with reduced ejection  fraction
PLOS ONE: Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction

Régulation différentielle de l'activité PKA cytoplasmique et nucléaire par  les récepteurs 1- et 2-ARs dans les cardiomy
Régulation différentielle de l'activité PKA cytoplasmique et nucléaire par les récepteurs 1- et 2-ARs dans les cardiomy

The Mammalian Ovary from Genesis to Revelation
The Mammalian Ovary from Genesis to Revelation

PLOS ONE: Evidence-based beta blocker use associated with lower heart  failure readmission and mortality, but not all-cause readmission, among  Medicare beneficiaries hospitalized for heart failure with reduced ejection  fraction
PLOS ONE: Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction